Cargando…

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

BACKGROUND: No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity against rGB. METHODS: Adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awada, Gil, Ben Salama, Laila, De Cremer, Jennifer, Schwarze, Julia Katharina, Fischbuch, Lydia, Seynaeve, Laura, Du Four, Stephanie, Vanbinst, Anne-Marie, Michotte, Alex, Everaert, Hendrik, Rogiers, Anne, Theuns, Peter, Duerinck, Johnny, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570224/ https://www.ncbi.nlm.nih.gov/pubmed/33067319 http://dx.doi.org/10.1136/jitc-2020-001146

Ejemplares similares

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
por: Duerinck, Johnny, et al.
Publicado: (2021)

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
por: Tijtgat, Jens, et al.
Publicado: (2023)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
por: Rogiers, Anne, et al.
Publicado: (2020)

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Rogiers, Anne, et al.
Publicado: (2019)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
por: Awada, Gil, et al.
Publicado: (2020)

Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava
por: Uematsu, Toshitaka, et al.
Publicado: (2022)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2020)

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
por: Suzuki, Issei, et al.
Publicado: (2021)

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
por: Uekawa, Ayano, et al.
Publicado: (2022)

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
por: Lu, Peiyao, et al.
Publicado: (2020)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
por: Shimizu, Nobuaki, et al.
Publicado: (2021)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
por: Solomon, Benjamin, et al.
Publicado: (2022)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
por: Choueiri, T.K., et al.
Publicado: (2021)

Pituitary carcinoma - case series and review of the literature
por: Du Four, Stephanie, et al.
Publicado: (2022)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
por: Choueiri, T. K., et al.
Publicado: (2020)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives
por: Duerinck, Johnny, et al.
Publicado: (2023)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
por: Galffy, G., et al.
Publicado: (2023)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
por: Bilen, Mehmet A., et al.
Publicado: (2022)

AV monografías = AV monographs.
Publicado: (1995)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

AV proyectos.
Publicado: (2004)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

AV timing in pacemaker patients with first-degree AV block: which is preferable, intrinsic AV conduction or pacing?
por: Aizawa, Yoshihiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a87e3odqqhtgmeki3saneh0ei6